News

Siegfried and Lonza secure top positions in global pharmaceutical outsourcing rankings

Valais-based pharmaceutical companies Lonza and Siegfried have been recognized among the leading players in the global outsourcing landscape, with respective rankings of 1st and 6th by Genetic Engineering & Biotechnology News.

CDMOs play a crucial role in the pharmaceutical sector, serving as key partners in the drug development and production process.
CDMOs play a crucial role in the pharmaceutical sector, serving as key partners in the drug development and production process.

Lonza and Siegfried, two renowned pharmaceutical firms based in the canton of Valais, have earned prominent places in the global rankings for pharmaceutical outsourcing. These accolades come amidst their consistent efforts in the domain of drug manufacturing and packaging at an industrial scale. The rankings offer insight into Switzerland’s notable contributions to the global pharmaceutical sector.

These rankings position these Western Switzerland giants alongside leading Contract Development and Manufacturing Organizations (CDMOs) from countries such as the United States, China, and South Korea. It’s noteworthy that Switzerland is the only nation with two representatives in the top 10, underscoring its significant role in the pharmaceutical outsourcing industry.

CDMOs play a crucial role in the pharmaceutical sector, serving as key partners in the drug development and production process. They provide critical outsourcing services to biotechnology and pharmaceutical companies, assisting in the transformation of drug concepts from initial research phases to clinical implementation.

A showcase of resilience and adaptability

Recent trends in the CDMO sector have been characterized by factors such as supply chain variations influenced by the pandemic, an influx of private equity transactions, and a movement towards comprehensive service models. Amid these evolving dynamics, companies like Siegfried and Lonza have showcased resilience and adaptability. The rankings further highlight a broader industry trend where companies are proactively investing in new technological advancements, enhancing their facility infrastructure, and exploring potential joint ventures.

For context on their recent activities, Lonza has announced a collaborative initiative with Vertex Pharmaceuticals for a new manufacturing facility in the US and has entered an agreement with Synaffix to enhance its bioconjugate offerings. Siegfried, in parallel, has reported a CHF 25 million investment towards a new R&D Center for Drug Substances in Evionnaz.

With Siegfried’s recent strategic moves, including the acquisition of a stake in DiNAMIQS and the establishment of a Development Center in Spain, coupled with Lonza’s expansion in the bioconjugate segment, these Valais-based companies continue to affirm their influential positions in the global pharmaceutical outsourcing arena.

Handbook for Investors

Our Handbook for Investors provides valuable information about technologies and production costs, taxes and financing, as well as the legal system and infrastructure in Switzerland. Browse through the complete handbook online or download the chapters most relevant to you.

Link

Condividere

Programma ufficiale